Barbary matrimony vine

Barbary Matrimony Vine (Lycium barbarum L.): A Comprehensive Reference

1. Identity: Botanical Classification, Names, and Plant Description

Lycium barbarum L. (family Solanaceae) is known by a range of common names, including Chinese wolfberry, goji berry, wolfberry, barbary matrimony vine, red medlar, and matrimony vine. The plant is called gugija in Korea and kuko in Japan. The botanical name L. barbarum was first assigned by the botanist Carolus Linnaeus in 1753.

Lycium barbarum, also designated "Chinese boxthorn" or "Lyciet de Barbarie" in French, belongs to the Solanaceae botanical family, and is thought to have probably originated from South-East Europe to South-West Asia, possibly the Mediterranean basin. Today it is predominantly cultivated in regions such as the Ningxia Hui and Xinjiang Uyghur Autonomous Regions of China. China is the largest producer of goji berries worldwide, accounting for approximately 95,000 tonnes annually, with L. barbarum being the most widely cultivated variety; the majority of these plantations are located in the Ningxia Hui Autonomous Region and the Xinjiang Uyghur Autonomous Region.

The plant is a deciduous shrub with a woody structure that reaches a height ranging from 1 to 3 meters. The berry is fusiform or oblong shaped with a length ranging from 6–20 mm and a diameter of 3–10 mm; the orange or dark red berry has a small stylar scar protruding from the top and a shrunken-appearing skin; the pulp is fleshy and soft with a bitter and sweet taste.

Pharmacopeial Designations and Related Species

Lycii Fructus, the fruit of Lycium barbarum and L. chinense, has historically been used in East Asia as both food and medicine. While only L. barbarum is officinal, the fruit (Fructus Lycii) and the root bark (Cortex Lycii radicis) of both species are used in folk medicine.

Common Forms and Preparations

The berry is eaten raw, consumed in juice form, or added to tea or wine; the fruit is also processed to make tinctures, powders, and tablets. Concentrated extracts and infusions prepared from the berries have a history of use as ingredients in various soft or alcoholic drinks marketed for their benefits to anti-aging, vision, kidney, and liver functions. While the berries and root bark are the parts of the plant most commonly used in Traditional Chinese Medicine (TCM), the leaves also have medicinal properties; TCM calls for the berries to be prepared as a decoction or ground into a powder and mixed with other herbs. The fruit is now sold as a health food in western countries, either dried or in juice.

2. Traditional and Historical Use

Traditional Chinese Medicine

Lycium barbarum has been used in China for more than 2,000 years as a traditional medicinal herb and food supplement. Its earliest mention is found in the ancient text "Shen Nong Ben Cao Jing" (The Classic of Herbal Medicine), written between 200 and 250 AD. Since the early 20th century, the plant has been commonly referred to as goji, derived from the Chinese term "Gou Qi."

In Traditional Chinese Medicine, Lycium barbarum, known as gou qi zi, has been utilized for over 2,000 years to tonify the liver and kidneys, enhance vision, and promote overall vitality, and is commonly prescribed for conditions including insomnia, diabetes, and infertility, often in formulations that balance yin and yang energies while nourishing essence and blood.

The species has been cultivated along the fertile floodplains of the Yellow River in northern and western China for more than 2,000 years, primarily for medicinal purposes, with records of systematic growth dating back to the Tang dynasty (618–907 CE). By the Ming dynasty (1368–1644 CE), cultivation expanded significantly, as noted in the Compendium of Materia Medica (Bencao Gangmu), which highlights its role in tonifying the liver and kidneys.

Lycium barbarum has a long tradition of use in traditional Chinese medicine; the berries are used for blurry vision and diminished visual acuity, infertility, abdominal pain, dry cough, fatigue, and headache, and to increase longevity and against prematurely gray hair. The herb is also used in TCM to protect the liver and kidneys and treat impotence and sperm discharge.

L. barbarum has been cultivated in China for over six centuries, and today is widely cultivated in the Ningxia Hui Autonomous Region situated in the north-central region of China. It is also cultivated to mitigate erosion and protect irrigated regions from desertification.

Use of Different Plant Parts

Various parts of the plant, including the root, fruit, and leaf, have been utilized in traditional medicine for their health-promoting properties. As to the root bark, several compounds have demonstrated a hepatoprotective action as well as inhibitory effects on the renin/angiotensin system, which may support the traditional use for the treatment of hypertension.

Introduction to Europe

The plant was introduced to Europe in the early 18th century, specifically to the United Kingdom around the 1730s by Archibald Campbell, the 3rd Duke of Argyll, who imported it from China along with tea plants. In the last two decades, Lycii Fructus has become more common in Western markets, where it is sold as "Goji berries" in food products ranging from trail mix to yogurt to juice.

3. Key Constituents and Active Compounds

Lycium barbarum contains abundant Lycium barbarum polysaccharides (LBPs), betaine, phenolics, carotenoids (zeaxanthin and β-carotene), cerebroside, 2-O-β-d-glucopyranosyl-l-ascorbic acid (AA-2βG), β-sitosterol, flavonoids, and vitamins (in particular, riboflavin, thiamine, and ascorbic acid). The leaves, fruits, and root bark of Lycium barbarum also contain alkaloids, amides, peptides, anthraquinones, coumarins, lignanoids, terpenoids, sterols, steroids, organic acids, anthocyanins, essential oils, and glycolipids.

Lycium barbarum Polysaccharides (LBPs)

LBPs are the primary active components of Lycium barbarum. LBPs comprise 5%–8% of the dried fruits. LBPs contain several monosaccharides and 17 amino acids, including rhamnose (Rha), galactose (Gal), glucose (Glc), arabinose (Ara), mannose (Man), and xylose (Xyl). Among various constituents, a group of polysaccharides (LBP) with a Glycan-O-Ser glycopeptide structure has been most researched and considered to be important for the efficacy of L. barbarum.

Carotenoids

The reddish-orange color of L. barbarum is derived from a group of carotenoids, which make up only 0.03–0.5% of the dried fruit; the predominant carotenoid is zeaxanthin, mainly as dipalmitate (also called physalien or physalin), making up about one-third to one-half of the total carotenoids.

Other Phenolic and Small-Molecule Constituents

Chlorogenic acid, p-coumaric acid, and ferulic acid are common compounds found in the leaves, flowers, and fruit parts of the plant. Also found are various small molecules, such as betaine, cerebroside, β-sitosterol, and p-coumaric acid, and various vitamins, amino acids, taurine, and γ-aminobutanoic acid, among others. The fruits of the plant are rich in phenolic compounds, flavonoids, ascorbic acid, and tocopherol; the plant also contains tannins, sterols, triterpenes, manganese, nickel, copper, chromium, and molybdenum; it also contains alkaloids, sugars, and hydrocyanic acid.

Variation by Plant Part

Various components of the plant, including the fruit, leaves, flower, root, and bark, were utilized for distinct purposes; the chemical and phenolic compositions documented exhibited variations depending on the specific parts utilized.

4. Mechanisms of Action

Antioxidant Activity

LBPs have been reported to mediate significant anti-aging effects through antioxidant, immunoregulative, and anti-apoptotic activities, and by reducing DNA damage. LBPs are complex polysaccharides isolated from the fruit of L. barbarum and show distinct roles as antioxidants. They are proven to be reasonably effective in preventing oxidative stress caused by excess free radicals.

Immunomodulation

In experimental models, LBPs antagonized the suppressive effect of cyclophosphamide on T-lymphocyte proliferation; inhibitory rate of cytotoxic T lymphocyte (CTL) activity was decreased in LBP-treated mice; administration of LBP restored reduced NK cell activity caused by cyclophosphamide; these results report a protective effect of LBP in augmenting T-cell-mediated immunity and NK cell activity.

Metabolic and Glucose-Regulating Mechanisms

LBP can modulate diabetes through various pathways, such as inhibiting α-amylase and α-glucosidase activities, promoting β-cell proliferation, stimulating insulin secretion, inhibiting glucagon secretion, improving insulin resistance and glucose tolerance, and enhancing antioxidant and anti-inflammatory activities. LBP can distinctly regulate the glucose metabolism of diabetic mice by activating up-regulated expressions of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY).

Neuroprotective Mechanisms

LBP has been proven to exhibit multiple pharmacological activities including antioxidant, neuroprotective, and anti-inflammatory effects, and evidence supports that LBP can enhance cognitive function and holds promise in counteracting Alzheimer's disease (AD). LBP not only attenuated NF-κB, TNF-α, IL-1β, IL-6, AChE, and oxidative/nitrosative stress levels but also increased IL-4, IL-10, and ACh levels and ChAT activity in the cortex of AD animal models.

Pharmacokinetics of LBPs

The primary constituents present in L. barbarum berries—mainly LBPs, polyphenols, carotenoids, tropane alkaloids, and others—undergo absorption, distribution, metabolism, and excretion (ADME) processes; studies showed that the adsorption kinetics of LBPs found in L. barbarum berries significantly dictate their efficacy, being transported via the bloodstream to various tissues. Most LBPs are absorbed through the gastrointestinal tract by oral administration rather than directly acting on the eyes, which may influence the efficiency of LBPs on the eye.

5. Scientific Evidence by Health Area

5.1 Antioxidant Effects and General Well-Being

A randomized, double-blind, placebo-controlled clinical trial—the first study reported from outside China that examined the general effects of orally consumed goji berry—administered a standardized juice (GoChi™) to healthy adults for 14 days. Measures assessed before and after consuming 120 mL of GoChi/day or placebo control solution included body weight, body–mass index, blood pressure, pulse rate, and visual acuity. These results clearly indicated that daily consumption of GoChi for 14 days increased subjective feelings of general well-being and improved neurologic/psychologic performance and gastrointestinal functions.

In a separate 30-day randomized, double-blind, placebo-controlled clinical study, the study population included 50 Chinese healthy adults aged 55 to 72 years. Participants were treated with Goji juice containing 13.6 mg/mL LBPs at a dose of 120 mL/day or placebo (n=25 each group); in vivo antioxidant markers including serum levels of SOD, GPx, and lipid peroxidation (indicated by the level of MDA) were determined before and after GoChi or placebo consumption for 30 days. SOD activity was significantly higher in groups treated with Lycium barbarum (about 8%) compared to levels observed in the control group (p<0.01), while GPx activity was increased 9.04% in the group treated with Lycium barbarum compared to the control group (p<0.01).

Evidence strength: Several clinical studies in healthy subjects show that consumption of wolfberry juice improves general wellbeing and immune functions. However, multiple trials were conducted by the same research group using a proprietary commercial product (GoChi), limiting independence of replication. Findings on subjective well-being relied on questionnaire measures, and effect sizes require confirmation in larger, independently funded trials.

5.2 Ocular Health

Comprehensive reviews have examined the antioxidant mechanisms of LBP and its potential applications in ocular diseases, including diabetic retinopathy, hypertensive neuroretinopathy, age-related macular degeneration, retinitis pigmentosa, retinal ischemia/reperfusion injury, glaucoma, dry eye syndrome, and diabetic cataract.

Glaucoma and retinal ganglion cells (preclinical): Chan et al. (2007) were the first to demonstrate the in vivo neuroprotective effects of LBP pre-treatment and investigated the dose-dependent efficacy using six LBP concentrations (0.01, 0.1, 1, 10, 100, 1000 mg/kg) in a glaucoma rat model. The polysaccharides extracted from Lycium barbarum (LBP) have been shown to be neuroprotective for retinal ganglion cells (RGCs) in different animal models, and protecting RGCs from secondary degeneration is a promising direction for therapy in glaucoma management.

Previous studies have verified that LBP, a kind of traditional Chinese medicine extract, exhibits neuroprotective effects in ischemia/reperfusion models and glaucomatous animals. LBP treatment reduced glial activation and decreased RAGE-associated damage to retinal neurons; however, a limitation of these animal studies is that the intraocular pressure induced in the experiment is much higher than that caused by the clinical disease, and the main mechanism of the acute ocular hypertension model only represents part of the pathogenesis of glaucoma.

Preclinical reviews describe the beneficial effects of LBP as a neuroprotective agent for retinal ganglion cells using preclinical animal models of optic neuropathies, while noting the challenges in effectively translating LBP neuroprotective therapies from preclinical to clinical use in glaucoma management.

Age-related macular degeneration (AMD): Scientific research has revealed that the consumption of goji berries facilitates retinal and macular functioning, enhances the protective effects exerted by ganglion cells on the retina, and decreases retinal ischemia injury. Additionally, goji berries have been associated with decreasing the risk of cataracts, preventing irreversible loss of central vision in older people, and ameliorating diabetic retinopathy, though much of this evidence remains at the preclinical or observational level.

Evidence strength: Evidence for ocular benefits is predominantly from preclinical animal models and in vitro studies. Available data indicate that antioxidant, immunomodulatory, and metabolic effects are predominantly supported by experimental studies, while human evidence is most consistent for ocular health outcomes, including plasma zeaxanthin levels and macular characteristics. Large, well-controlled human RCTs specifically assessing ocular endpoints with L. barbarum remain limited.

5.3 Immune Function

Several clinical studies in healthy subjects show that consumption of wolfberry juice improves general wellbeing and immune functions. To examine the systematic effects of L. barbarum on immune function, general well-being, and safety, researchers tested the effects of a standardized L. barbarum fruit juice (GoChi) at 120 mL/day, equivalent to at least 150 g of fresh fruit.

Evidence strength: Immunomodulatory effects in humans are supported by a small number of clinical trials, primarily short-duration (14–30 days), in healthy subjects. Mechanistic data in human immune cells remain limited compared to the extensive preclinical literature. Independent replication is needed.

5.4 Metabolic Effects: Blood Glucose and Lipids

Studies have found that LBP possesses activities of hypoglycemic, lowering blood lipids, anti-inflammatory, antioxidant, and antitumor properties; the effects of LBP on improving insulin sensitivity, regulating blood lipids, and reducing blood glucose have attracted particular attention. Research examining the hypoglycemic and hypolipidemic characteristics of L. barbarum bark has revealed its ability to decrease blood glucose and lipid levels, improve sugar metabolism, boost insulin production, and stimulate weight gain in animal models, suggesting that LB barks can potentially be used as a treatment for diabetes.

In animal studies, reduced body weight and enhanced blood glucose concentration in serum were observed in diabetic rats, and they were significantly normalized by LBP at doses of 100, 250, and 500 mg/kg. LBP also inhibited albuminuria and blood urea nitrogen concentration and serum levels of inflammatory factors including IL-2, IL-6, TNF-α, IFN-α, MCP-1, and ICAM-1 compared with diabetic rats, indicating protection against renal damage.

Evidence strength: Evidence for blood glucose and lipid effects is predominantly from animal and in vitro studies. Human clinical evidence is limited and requires larger, well-controlled trials for confirmation.

5.5 Anti-Aging and Longevity

LBPs have been reported to mediate significant anti-aging effects through antioxidant, immunoregulative, anti-apoptotic activities and by reducing DNA damage; the basic scientific evidence for anti-aging effects of LBPs is already available, but additional studies are needed to understand the mechanisms by which LBPs mediate anti-aging properties.

Evidence strength: Anti-aging evidence is largely preclinical (animal models and cell culture). Human clinical evidence is preliminary.

5.6 Neuroprotection and Cognitive Function

Lycium barbarum extracts (LBE) have been demonstrated to be neuroprotective in various animal models of neurodegeneration. After 2 months of LBE treatment in 5xFAD transgenic Alzheimer's mice, the decline in cognition, motor, and visual functions was significantly slowed; microglia in the brain, spinal cord, and retina exhibited a neuroprotective state, with reduced Aβ deposition, decreased inflammatory cytokine levels (e.g., TNF-α, IL-1β, IL-6), increased Arg-1/iNOS ratio, and enhanced phagocytic capacity.

In an Alzheimer's disease rat model, LBP significantly reversed cognitive impairments assessed through the Y-maze, Passive Avoidance Test, and Morris water maze test; LBP not only attenuated NF-κB, TNF-α, IL-1β, IL-6, AChE, and oxidative/nitrosative stress levels but also increased IL-4, IL-10, and ACh levels and ChAT activity in the cortex.

Evidence strength: Neuroprotective and cognitive effects are currently demonstrated exclusively in animal models. No robust human clinical trials on cognitive outcomes have been published as of this writing. Evidence is preclinical only and should be interpreted cautiously.

5.7 Antitumor Activity

LBPs show antitumor activities against various types of cancer cells and inhibit tumor growth in nude mice through induction of apoptosis and cell cycle arrest. LBPs show antitumor activities against various types of cancer cells and inhibit tumor growth in nude mice through induction of apoptosis and cell cycle arrest.

Evidence strength: Antitumor evidence is exclusively from in vitro cell culture studies and animal (xenograft) models. No clinical trials in cancer patients have established efficacy. This evidence base is preliminary and does not support clinical use for oncological indications.

5.8 Body Weight and Energy Expenditure

Two human clinical studies were conducted to explore the acute effects of L. barbarum on resting metabolic rate (RMR) and postprandial energy expenditure (PPEE) as measured by indirect calorimetry, and central adiposity measured by waist circumference using GoChi®; a single bolus of L. barbarum intake increased postprandial energy expenditure 1 through 4 hours post-intake over baseline in a dose-dependent manner; in a 14-day intervention trial, individuals consuming L. barbarum exhibited significantly decreased waist circumference.

Evidence strength: These findings are preliminary, based on small trials with a commercially sponsored product. Independent replication has not been established.

6. Body Systems and Health Areas Associated with Lycium barbarum

• Visual system: Retinal ganglion cell protection; possible benefits in glaucoma, AMD, diabetic retinopathy, retinitis pigmentosa, dry eye syndrome, and cataract prevention — primarily supported by preclinical evidence with some human biomarker data (zeaxanthin, macular pigment).
• Immune system: Immunomodulation, T-cell and NK-cell activity enhancement — supported by preclinical models and a small number of short human trials.
• Metabolic system: Blood glucose regulation, improvement in insulin sensitivity, lipid-lowering effects — supported by animal models and limited human data.
• Nervous system: Neuroprotection in models of Alzheimer's disease, Parkinson's disease, stroke, and optic neuropathy — preclinical evidence only.
• Hepatic and renal systems: Hepatoprotective and nephroprotective effects — predominantly animal and in vitro evidence.
• Cardiovascular system: Key health benefits include immune modulation, antioxidative effects, mental health support, ocular health preservation, and metabolic and cardiovascular regulation.
• Reproductive system: Traditional use for infertility; traditional use for facilitating male fertility — not yet supported by rigorous clinical trials.
• Mental health: Studies have explored the effects of Lycium barbarum polysaccharides on cytokines in adolescents with subthreshold depression in randomized controlled settings. Evidence is very preliminary.

7. Dosage Forms and Dosages Reported in Studies

In the Amagase and Nance (2008) randomized placebo-controlled trial, participants consumed 120 mL of GoChi/day for 14 days. This dose of 120 mL/day was described as equivalent to at least 150 g of fresh fruit.

In the 30-day antioxidant clinical study, 50 Chinese healthy adults were treated with Goji juice containing 13.6 mg/mL LBPs at a dose of 120 mL/day or placebo.

Randomized, double-blind, placebo-controlled clinical trials used daily consumption of Goji juice equivalent to 150 g of fresh berries for 14 days.

In animal studies, dosages reported include:

• Six LBP concentrations (0.01, 0.1, 1, 10, 100, 1000 mg/kg) in a glaucoma rat model.
• Animals fed with LBP solution (1 mg/kg) or vehicle daily from 7 days before the AOH insult through sacrifice.
• LBP doses of 100, 250, and 500 mg/kg in diabetic rats.
• Rats orally administered LBP at 150 and 300 mg/kg once a day in an Alzheimer's disease model.
• 5xFAD mice received daily intragastric gavage of LBE at 2 g/kg for 2 months.

These animal dosages are not directly translatable to human use and are reported here only as described in the cited literature.

8. Safety Considerations and Known Drug Interactions

General Safety Profile

LBP is described as relatively safe and non-toxic in the reviewed literature. While there are no signs of toxicity of this plant in the general literature, two cases of possible interaction with warfarin point to a potential risk of drug interaction.

Warfarin Interaction: Case Reports

The most clinically significant documented safety signal for L. barbarum is a pharmacokinetic interaction with the anticoagulant warfarin, supported by multiple published case reports.

An elevated INR of 4.1 was observed in a 61-year-old Chinese woman, previously stabilized on anticoagulation therapy (INR 2–3); with no changes in her other medications or lifestyle, a review of her dietary habits revealed four days of drinking a concentrated Chinese herbal tea made from Lycium barbarum L. fruits (3–4 glasses daily) prior to her clinic visit. A follow-up INR seven days later was 2.4, and seven subsequent INR values were in the 2.0–2.5 range.

In vitro evaluation showed inhibition of S-warfarin metabolism by CYP2C9 by the tea of L. barbarum L.; however, the inhibition observed was weak, with a dissociation constant (Ki) value of 3.4 mg/mL, suggesting that the observed interaction may be caused by factors other than the CYP450 system.

A separate case described a 71-year-old Ecuadorean-American woman who was taking warfarin and was hospitalized for a markedly elevated, indeterminate international normalized ratio (INR, prothrombin time >120 sec) after consumption of goji juice; she had undergone knee surgery approximately 3 months earlier at which time warfarin therapy was started; she reported no changes in dietary habits or lifestyle other than drinking goji juice for 4 days before hospitalization.

Application of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 6) between the patient's elevated INR with associated bleeding and her concomitant use of L. barbarum and warfarin; two other published reports have described similar interactions between warfarin and a tea containing L. barbarum.

However, given the high frequency of use of L. barbarum fruit and of warfarin, the lack of more reports of interaction suggests that the incidence may be very low.

There is a potential herbal-drug interaction between warfarin and L. barbarum L. based on an increased INR value noted with concurrent use; thus, combination of L. barbarum L. and warfarin should be avoided.

Drugs with Narrow Therapeutic Index

In vitro inhibitions of CYP2C9 and CYP3A4 by fractions isolated from goji berry fruits have been documented; since drug interactions are not known precisely, it is recommended not to be used with drugs with a narrow therapeutic index.

Evidence Gaps and Limitations

Despite promising findings, gaps in the evidence base, including the need for larger, long-term, and rigorously controlled trials, remain significant barriers to clinical translation. Additional studies are needed to understand mechanisms by which LBPs mediate anti-aging properties; novel findings from such studies would likely pave the way for the clinical application of traditional Chinese medicine Lycium barbarum in modern evidence-based medicine.

References

• Gao Y, Wei Y, Wang Y, Gao F, Chen Z. Lycium Barbarum: A Traditional Chinese Herb and A Promising Anti-Aging Agent. Aging Dis. 2018;9(1):117–137. PMC5758351
• Gao et al. Lycium Barbarum: A Traditional Chinese Herb and A Promising Anti-Aging Agent. PubMed 29344416
• Cheng J, Zhou ZW, Sheng HP, et al. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther. 2015;9:33–78. PMC4277126
• Cheng et al. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. PubMed 25552899
• Berisha A, Alexa EA, Kelleher R, Zhang T. From botany to bedside: a review of the health benefits of Lycium barbarum as a functional food. Explor Foods Foodomics. 2025;3:101070
• Amagase H, Nance DM. A Randomized, Double-Blind, Placebo-Controlled, Clinical Study of the General Effects of a Standardized Lycium barbarum (Goji) Juice, GoChi™. J Altern Complement Med. 2008;14(4):403–412
• Amagase H, Sun B, Borek C. Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults. Nutr Res. 2009;29(1):19–25. PubMed 19185773
• Lakshmanan Y et al. Potential role of Lycium barbarum polysaccharides in glaucoma management: evidence from preclinical in vivo studies. PMC10358649
• Distinct Role of Lycium barbarum L. Polysaccharides in Oxidative Stress-Related Ocular Diseases. PMC9966716
• Lycium Barbarum Polysaccharides Reduce Neuronal Damage, Blood-Retinal Barrier Disruption and Oxidative Stress in Retinal Ischemia/Reperfusion Injury. PMC3027646
• Protection of Retinal Ganglion Cells and Retinal Vasculature by Lycium Barbarum Polysaccharides in a Mouse Model of Acute Ocular Hypertension. PMC3477168
• Evaluation of the Anti-Alzheimer Activity of Lycium barbarum Polysaccharide in Aβ1–42-Induced Neurotoxicity in Rat Model. PMC12025514
• Lycium barbarum Extract Enhanced Neuroplasticity and Functional Recovery in 5xFAD Mice via Modulating Microglial Status of the Central Nervous System. PMC11576918
• Preservation of Retinal Function Through Synaptic Stabilization in Alzheimer's Disease Model Mouse Retina by Lycium Barbarum Extracts. Front Aging Neurosci. 2021
• Lycium barbarum Polysaccharide Mediated the Antidiabetic and Antinephritic Effects in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats via Regulation of NF-κB. PMC4856889
• Lycium barbarum's diabetes secrets: A comprehensive review of cellular, molecular, and epigenetic targets. ScienceDirect 2024
• Potential of Lycium barbarum polysaccharide for the control of glucose and lipid metabolism disorders: a review. Int J Food Prop. 2022
• Lam AY, Elmer GW, Mohutsky MA. Possible Interaction between Warfarin and Lycium Barbarum L. Ann Pharmacother. 2001;35(10):1199–1201
• Warfarin overdose due to the possible effects of Lycium barbarum L. Food Chem Toxicol. 2008
• Rivera CA, Ferro CL, Bursua AJ, Gerber BS. Probable Interaction Between Lycium barbarum (Goji) and Warfarin. Pharmacotherapy. 2012;32:e50–e53
• Probable interaction between Lycium barbarum (goji) and warfarin. PubMed 22392461
• Sevindik et al. A Comprehensive Review on the Biological Activities, Usage Areas, Chemical and Phenolic Compositions of Lycium barbarum Used in Traditional Medicine Practices. Science and Technology Indonesia. 2025;10:173–182
• Lycium barbarum – Overview. ScienceDirect Topics (Pharmacology)
• Recent Progress of Research on Herbal Products Used in Traditional Chinese Medicine: herbs belonging to The Divine Husbandman's Herbal Foundation Canon. PMC3943012
• Health Benefits and Food Applications of Bioactive Constituents From Different Medicinal Parts (Bark, Leaf, and Fruit) of Lycium barbarum. PMC12481216